<DOC>
	<DOC>NCT02904096</DOC>
	<brief_summary>The primary objective of this study is to evaluate the safety of Radiesse implantation for very severe volume loss in the dorsum of the hand at 6 months after treatment.</brief_summary>
	<brief_title>RadiesseÂ® Safety Study For the Treatment of Hands</brief_title>
	<detailed_description>This is a 2-year post approval safety (PAS) study evaluating the Adverse Event (AE) rate of Merz Hand Grading Scale (MHGS) baseline grade 4 hands (Group A) compared to the AE rate of MHGS baseline grade 2-3 hands (Group B). Subjects will be recruited at each site with the intention to have an equal number of subjects in Group A and Group B. All subjects will receive an initial Radiesse hand treatment in both hands, and up to 3 retreatments in the study. Hands will be assessed by evaluators on the MHGS who will be blinded to group, treatment details, time since last treatment, and number of retreatments.</detailed_description>
	<mesh_term>Lidocaine</mesh_term>
	<criteria>1. Has hands rating 2, 3, or 4 on the validated MHGS as determined by a live, masked evaluator. 2. Is at least 22 years of age. 3. Understands and accepts the obligation not to receive any other procedures in the dorsum of the hands through the end of the study. 4. Understands and accepts the obligation and is logistically able to present for all scheduled followup visits and meet all study requirements. 1. Was a participant in the Radiesse hands premarket clinical study 2. Has been treated with fat injections or Radiesse in the hands, has hand deformities, or has received surgery in the dorsum of the hands. 3. Has any medical condition with the potential to interfere with the study or increase the risk of AEs.</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>